Wellgistics Health (WGRX) experienced a dramatic surge on Monday, with shares more than doubling after the company announced it was withdrawing preliminary proxy materials to review potential strategic transactions. The stock closed at $0.1740, a gain of 108.38%, on volume exceeding 614 million shares—roughly 39 times the average.
The Tampa, Florida-based drug distribution and health-tech firm said in an 8-K filing that it asked the Securities and Exchange Commission to pull a preliminary proxy statement filed May 14. Wellgistics noted it is not moving forward with the proxy in its current form as it evaluates strategic alternatives, leaving investors speculating about the company's next moves.
Investors are now focused on the upcoming first-quarter earnings report, scheduled for release on Tuesday, May 19. The company confirmed the earnings date on Friday, alongside a notification that its 10-Q filing would be delayed due to the need for additional time to complete financial statements and disclosures. Wellgistics expects to file within the allowed five-day extension and does not anticipate material changes from the prior-year period.
Strategic Acquisition in Play
The stock's rally also follows deal chatter after Wellgistics announced a non-binding letter of intent to acquire WellCare Today for approximately $15 million. The deal includes $3 million in cash and preferred stock as an earnout. WellCare Today specializes in remote patient monitoring, remote therapeutic monitoring, and chronic care management, utilizing Samsung Galaxy Watch technology to track health metrics such as heart rate and blood oxygen levels.
Wellgistics described the acquisition as an extension of a pilot program with Kare PharmTech and Kare Clinicals announced earlier in May. President and CEO Prashant Patel noted the partnership could create a "significant opportunity" for patient outcomes and independent pharmacies. However, the transaction remains subject to due diligence, a final agreement, board approval, financing, and other conditions.
Financial and Competitive Pressures
Despite Monday's surge, Wellgistics faces significant headwinds. The company reported $23.34 million in revenue for 2025 but posted a net loss of $101.27 million. Cost of revenue exceeded sales, resulting in negative gross margins due to liquidity constraints and aged inventory. The stock continues to trade well below Nasdaq's $1 minimum bid requirement, with a compliance deadline of June 8. Failure to meet the threshold could lead to delisting unless an extension is granted.
Competition is intense in the pharmacy and healthcare distribution sectors. Wellgistics competes against major players such as CVS Health, Cencora, and McKesson, which control significantly greater resources and market share. The company's market capitalization stood at approximately $21.9 million at Monday's close, highlighting its relatively small scale.
Investors remain cautious about the company's ability to execute on its strategic plans and address its financial challenges. The non-binding nature of the WellCare Today deal and the ongoing proxy withdrawal underscore the uncertainty surrounding Wellgistics' next steps.
